A second chance for a PPARγ targeted therapy?
Where this comes from
- Record sourced from PubMed, PMID 22223206.
- Also identified by DOI 10.1161/RES.0b013e3182435d88 and PMC identifier 3583552.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new class of non-agonist ligands target the transcription factor PPARγ and promote expression of insulin-sensitizing adipokines. They have potent antidiabetic actions, yet they lack several of the adverse effects commonly associated with thiazolidinediones. The ligands may represent a new class of anti-diabetes medications that preserve the most beneficial effects of PPARγ activation without imparting major side effects, which have limited the clinical usefulness of thiazolidinediones.
Medical subject headings
- Diabetes Mellitus
- Hypoglycemic Agents
- PPAR gamma